To determine whether pharmacological activation of A2ARs could mitigate D2R antagonist-induced dyskinesia, we intraperitoneally injected a haloperidol-induced VCM mouse model with CGS 21680A, an A2AR agonist. The gene discussed is DRD2; the disease is Dyskinesia.